2017

Nicox to present at the Deutsche Bank 42nd Annual Health Care Conference

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Gavin Spencer, Executive Vice President, Corporate Development, will present at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3rd, 2017 at 9:20 a.m. Eastern Time. The conference is being held at the InterContinental Boston Hotel.
The presentation will be available on Nicox website (www.nicox.com) in “Presentations &

Read more

Nicox announces PDUFA date for ZERVIATE NDA

  • PDUFA date set for September 8, 2017

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of September 8, 2017 for its decision on the New Drug Application (NDA) for ZERVIATE1 (cetirizine ophthalmic solution) 0.24%,

Read more

Nicox’s Extraordinary and Ordinary Shareholder Meetings

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, has convened an ordinary and extraordinary shareholder meeting on Tuesday May 16, 2017 at 2:00 pm CET in the offices of Drakkar – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.
The documents mentioned in articles R.225-73-1 of the French Code de commerce,

Read more

Nicox to present at the 16th Annual Needham Healthcare Conference

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Gavin Spencer, Executive Vice President, Corporate Development, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 9:20 a.m. Eastern Time. The conference is being held at the Westin Grand Central in New York.
The presentation will be available on Nicox website (www.nicox.com) in “Presentations &

Read more

Nicox: Business Update and 2016 Financial Results

  • Two potential U.S. product approvals for Vyzulta™1 (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE2 (cetirizine ophthalmic solution) 0.24% expected in 2017
  • Strong pipeline including two products poised to enter in Phase 2 clinical trials
  • Significant reduction in future fixed costs
  • Cash position of €28.9 million as of December 31,
Read more

Bausch + Lomb announce PDUFA date for novel glaucoma candidate latanoprostene bunod

PDUFA date set for August 24, 2017
LAVAL, QUEBEC and SOPHIA ANTIPOLIS, FRANCE – March 20, 2017 – Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of August 24,

Read more

Nicox resubmits AC-170 (ZERVIATE) NDA to the U.S. FDA

  • CGMP issues at the API manufacturer have been resolved
  • NDA resubmitted on March 8, 2017
  • ZERVIATE as the brand name provisionally approved by the U.S. FDA for AC-170

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced the resubmission of the New Drug Application (NDA) for AC-170,

Read more

Nicox to participate at two upcoming investor conferences

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that members of the management team will participate in the following investor conferences in March 2017 in the United States:
• Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7 at 9:20 a.m. ET at the Boston Marriott Copley Place in Boston.

Read more

Bausch + Lomb and Nicox resubmit US New Drug Application for novel glaucoma candidate latanoprostene bunod

LAVAL, QUEBEC and SOPHIA ANTIPOLIS, FRANCE – FEBRUARY 27, 2017 – Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. (NYSE Euronext Paris: COX) today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for latanoprostene bunod ophthalmic solution,

Read more

Nicox announces the presentation of NCX 667 scientific data at AOPT 2017

New preclinical data demonstrate NCX 667’s robust IOP lowering properties
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19,

Read more

Nicox to present at the 6th Annual LEERINK Partners Global Healthcare Conference

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 6th Annual LEERINK Partners Global Healthcare Conference on Thursday, February 16th, 2017 at 3:00 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.

Read more

Nicox provides clinical and regulatory update for NCX 470 for IOP lowering

  • Positive pre-IND meeting with FDA completed
  • Expect to file IND in Q4 2017
  • First-in-Human Phase 2 clinical study expected to start in Q1 2018

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today provided certain regulatory and clinical updates for NCX 470,

Read more

Nicox provides clinical and regulatory update for NCX 4251 in blepharitis

  • Pre-IND meeting on NCX 4251 with FDA completed
  • Phase 2 expected to start Q4 2017

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today provided certain regulatory and clinical updates for NCX 4251, its novel ophthalmic suspension of fluticasone propionate nanocrystals being developed for the first time as a topical treatment for acute exacerbation of blepharitis.

Read more

2016

Nicox to present at the Stifel 2016 Healthcare Conference

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0000074130, COX), today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016, at 11:00 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.
The presentation will be available on the Company’s website (www.nicox.com) in “News &

Read more

Nicox Provides Update on Latanoprostene bunod and AC-170

  • Latanoprostene bunod: Bausch + Lomb anticipates launch mid-20171

 

  • AC-170: Nicox to meet with the FDA concerning resubmission of AC-170 NDA and expects FDA feedback by early 2017

 
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today provided an update on the regulatory status of its key projects,

Read more

Nicox third quarter 2016 business update and cash position

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today provided an update on its activities and cash position.
We expect to further advance our position as a leading ophthalmic R&D company with the anticipated FDA decisions on latanoprostene bunod, which is licensed worldwide to Bausch + Lomb, and AC-170,

Read more

Nicox Receives Complete Response Letter from the FDA Related to GMP on NDA for AC-170

  • Safety and efficacy data submitted in the NDA have not resulted in the FDA requesting any further clinical or non-clinical testing for approval
  • FDA letter related solely to GMP at third party active pharmaceutical ingredient supplier facility

 
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company,

Read more

WARNING

We regretfully announce a fraudulent use of the name Nicox with respect to alleged job offers in our Group, in particular in the United-States. All our job offers appear in the “Working with us” section of our website. Nicox Ophthalmics, Inc., our American subsidiary, is not currently recruiting.
All job offers that are not listed in the “Working with us” section of our website should be considered spam and all entities of the Group decline any and all liability in this respect.

Read more

Shareholder Letter

Dear Shareholder,
I am writing to you personally today, following comments that we have received and noted, concerning the status of latanoprostene bunod and to assure you that we are fully engaged on the subject following the receipt of the US Food and Drug Administration (FDA) letter by Bausch + Lomb in July.
We are in close discussion with the team at the headquarters of Bausch + Lomb however certain information cannot be publicly disclosed by Nicox at the moment due to the fact that it relates to discussions between Bausch + Lomb and the FDA.

Read more

Nicox first half 2016 business and financial update

  • Latanoprostene bunod licensee Bausch + Lomb receives Complete Response Letter from U.S. FDA pertaining to B+L manufacturing facility; no efficacy or safety concerns or additional clinical trials regarding the compound identified for approva
  • AC-170 NDA under FDA Priority Review approval process
  • Cash position of €34.1 million1: Nicox sufficiently financed through completion of clinical proof-of-concept trials for pipeline assets NCX 4251 and NCX 470 by end of 2018
  • Refocusing on R&D-only allows significant reduction in operating costs going forward

………………………………………………………………………
Sophia Antipolis,

Read more

Nicox to present at the 18th Annual Rodman & Renshaw Global Investment Conference

Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Gavin Spencer, EVP Corporate Development, will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 13, 2016 at 2:35 PM Eastern Time. The conference is being held at the Lotte New York Palace Hotel in New York City.

Read more

Nicox completes transfer of Commercial Operations to new pan-European Ophthalmic Specialty Pharmaceutical Company led by GHO Capital

Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of the transfer of its European and International commercial operations and related late-stage development programs to a newly-founded, private, pan-European ophthalmic specialty pharmaceutical company. This transfer includes the affiliates Nicox Pharma (France), together with its Spanish and UK operations,

Read more

Shareholder Letter

Dear Nicox Shareholder,
As you may have noticed this has been without doubt an intense few weeks for Nicox, with the US FDA granting Priority Review for our New Drug Application (NDA) for AC-170 on June 18th, followed by the signing of an innovative agreement with GHO Capital for the future development of our European Commercial operations on July 4th.

Read more

Nicox raises €18 million to finance development of its pipeline

  • Proceeds to finance development of NCX 4251 in blepharitis and NCX 470 in glaucoma and for general corporate purposes

………………………………………………………………………………………….
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced a reserved capital increase of ordinary shares of the Company to a specific category of investors. The proceeds from the financing will principally be used to drive the development of NCX 4251,

Read more

Press Release concerning latanoprostene bunod

Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, has been informed by its partner Bausch + Lomb (a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.) of the receipt of a Complete Response Letter from the U.S. FDA concerning latanoprostene bunod which resulted in the attached press release issued by Valeant today.

Read more

Nicox to present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), today announced that Gavin Spencer, Executive Vice President Corporate Development of Nicox, will be presenting at the Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Wednesday July 13, 2016, at 1:30 pm Eastern Time. The conference is being held at Le Parker Meridien hotel in New York.
The presentation will be available on the Company’s website (www.nicox.com) in “News &

Read more

Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology

Second Published Phase 3 Trial to Demonstrate Significantly Greater Efficacy vs. Timolol Maleate 0.5%
LAVAL, QUEBEC and SOPHIA ANTIPOLIS, FRANCE – JULY 6, 2016 – Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, and Nicox S.A. (Euronext Paris: COX) today announced that the results of a Phase 3 study for latanoprostene bunod (LBN) ophthalmic solution 0.024% have been published in the American Journal of Ophthalmology.

Read more

Nicox to transfer Commercial Operations to new pan-European Ophthalmic Specialty Pharmaceutical Company led by GHO Capital

  • Transaction values Nicox’s European and International commercial operations and related late-stage development programs at up to €26 million
  • Nicox to receive a €9 million upfront cash payment and a minority stake in the new company
  • Nicox to focus resources on unencumbered R&D pipeline in ophthalmology
    ………………………………………………………………………………………….
    Sophia Antipolis, France.

Nicox S.A.

Read more

Nicox added to Russell Global Index

Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that it was added to the Russell Global Index when the Russell Investment Group reconstituted its family of U.S. indexes effective today, June 27, 2016.
Membership in the Russell Global Index, which remains in place for one year, means automatic inclusion in the appropriate large-cap,

Read more

U.S. FDA grants Priority Review for Nicox’s AC-170 New Drug Application

FDA assigns Prescription Drug User Fee Act (PDUFA) goal date of October 18, 2016
…………………………………………………………………………………………. 
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for AC-170, a novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis.

Read more

Nicox’s Ordinary Shareholder Meeting

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, has convened an Ordinary shareholder meeting on a second call and on same agenda on Tuesday June 21, 2016 at 2:00 pm CET at BuroClub – room Colomb – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France as the quorum required by law was not reached on first call on June 7,

Read more

Nicox first quarter 2016 financial and business update

  • Revenue of €3.5 million, with growth of over 60% in the first quarter 2016
  • NDAs in the U.S. for latanoprostene bunod and AC-170 under review at the FDA

………………………………………………………………………………………….
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today reported its first quarter 2016 revenues and cash position and provided an update on its activities.

Read more

Nicox announces the presentation of scientific data at ARVO 2016

Study results on Nicox compounds presented, including internally-developed pipeline candidates NCX 667, NCX 1653 and NCX 4240, as well as latanoprostene bunod results presented by licensee Bausch + Lomb
………………………………………………………………………………………….
Sophia Antipolis, France 
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the presentation of seven posters highlighting scientific data for its internally developed and partnered pipeline candidates at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting,

Read more

Nicox’s Ordinary Shareholder Meeting

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, has convened an ordinary shareholder meeting on Tuesday June 7, 2016 at 2:00 pm CET at BuroClub – room Colomb – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.
The documents mentioned in articles L.225-115,

Read more

Nicox submits New Drug Application for AC-170 to U.S. FDA

Dossier submitted, with a request for Priority Review, for the treatment of ocular itching associated with allergic conjunctivitis
………………………………………………………………………………………….
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the submission, through its American subsidiary Nicox Ophthalmics, Inc., of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AC-170,

Read more

Nicox: 2015 Financial Results and Business Update

  • Latanoprostene bunod New Drug Application (NDA) under review by the U.S. Food & Drug Administration (FDA) with a PDUFA (Prescription Drug User Fee Act) date of July 21, 2016
  • AC-170 NDA to be submitted early Q2, 2016
  • 2015 revenues €10 million, a 67% increase vs. 2014
    ……………………………………………………………………………………….

Sophia Antipolis,

Read more

Nicox to present at the 15th Annual Needham Healthcare Conference

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 1:40 pm Eastern Time. The conference is being held at The Westin NY Grand Central Hotel in New York City.
A live webcast of the presentation can be accessed on the Company’s website (www.nicox.com) in “News &

Read more

Nicox reports strong revenue growth in 2015 and provides corporate update

  • 2015 annual revenues grew by 65% to €9.9 million
  • NDA filing for AC-170 expected in early Q2 2016

 
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today reported the unaudited revenues and cash position for the full year 2015 and provided an update on its corporate activities.

Read more

Nicox to present at the 18th Annual BIO CEO & Investor Conference

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:00 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City.
A live webcast of the BIO CEO &

Read more

Nicox out-licenses OTC asset AC-120 to Ora, Inc.

  • Transaction enables Nicox to leverage OTC-directed asset from Aciex acquisition, while focusing resources on its ophthalmic pipeline assets targeting major prescription markets
  • Nicox to receive payment on approval and a share of future revenue from sales of AC-120
  • Ora to finance all development activities
  • Upcoming Phase 2/3 in morning eyelid swelling or ‘puffiness’

Sophia Antipolis,

Read more

2015

Nicox completes reverse stock split and provides business update

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of its reverse stock split and provided an update regarding ongoing corporate initiatives and activities.
Completion of the 5-for-1 reverse stock split
The Company has completed the previously announced 5-for-1 reverse split of its common stock, effective today. The reverse stock split,

Read more

Nicox to present at the Stifel 2015 Healthcare Conference

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0000074130, COX), today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the Stifel 2015 Healthcare Conference in New York City on Wednesday November 18, 2015, at 11:45 am EST (5:45pm CET) .
A live webcast of the presentation can be accessed under the “Presentations &

Read more

Nicox and Fera Pharmaceuticals sign exclusive license agreement for naproxcinod in the U.S.

Nicox eligible to receive up to $35 million in commercial milestones, plus 7% royalties on future sales
Sophia Antipolis, France and Locust Valley, New York
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, and Fera Pharmaceuticals, a privately-held specialty pharmaceutical company, announced today that they have entered into an exclusive license agreement for the development and commercialization of Nicox’s naproxcinod,

Read more

Nicox third quarter 2015 financial and business update

Total sales increased by almost 120% over 2014
………………………………………………………………………………………….
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today reported its revenues for the nine month to September 30, 2015 as well as its cash position, and provided an update on its activities.
Michele Garufi, Chairman and Chief Executive Officer of Nicox,

Read more

Nicox announces reverse stock split

Important step in the Company’s strategic initiative to increase international awareness and visibility
………………………………………………………………………………………….
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that its Board of Directors is implementing a 5-for-1 reverse stock split, as approved by Nicox’s shareholders at the October 13, 2015 Extraordinary General Meeting. The reverse stock split will become effective on December 3,

Read more

Nicox to present at the 14th Annual BIO Investor Forum

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0000074130, COX), today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 14th Annual BIO Investor Forum in San Francisco on Tuesday October 20, 2015, at 10:00 am Pacific Time.
A live webcast of the BIO Investor Forum presentation can be accessed under the “Presentations &

Read more

Nicox proposes reverse stock split and convenes Extraordinary Shareholder Meeting

Sophia Antipolis, France.
Download the presentation
Nicox S.A. (Euronext Paris: FR0000074130, COX) has convened an Extraordinary Shareholder Meeting on Tuesday October 13, 2015 at 2:00 pm CET, at the Hotel Sophia Country Club – 3550 Route des Dolines, 06410 Biot (Sophia Antipolis), France.
The first resolution submitted to the vote of the shareholders is a delegation of powers to the Board of Directors to carry out a reverse stock split with a 5 to 1 ratio1.

Read more

Nicox first half 2015 highlights

• Product pipeline on track for near-term major progress
       o VESNEO™ NDA submitted by Valeant
       o Three further regulatory submissions planned by Nicox within the next 12 months
• Accelerating development of additional NO-donating ophthalmology programs
• Revenues from existing products €4.6 million in H1 2015, up 114% from H1 2014 ………………………………………………………………………………………….
Sophia Antipolis, France
Nicox S.A.

Read more

Bausch + Lomb confirms submission of Vesneo™ NDA to US FDA

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today noted the confirmation by Valeant Pharmaceuticals International, Inc’s. (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb,that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for VESNEO™ (latanoprostene bunod ophthalmic solution 0.024%),

Read more

Nicox provides business update at Ordinary and Extraordinary Shareholder Meetings

  • Lead clinical candidates Vesneo™ and AC-170 on track for NDA submission in the United States
  • New preclinical nitric oxide-donating programs moving forward

………………………………………………………………………………………….Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today provided an update ahead of its Ordinary and Extraordinary Shareholder Meetings, convened today, June 3,

Read more

Nicox to present at the Jefferies 2015 Healthcare Conference

Sophia Antipolis, France.

Nicox S.A. (Euronext Paris: FR0000074130, COX), today announced that Gavin Spencer, EVP Corporate Development of Nicox, will be presenting at the Jefferies 2015 Healthcare Conference in New York on Thursday June 4th at 11:30 am EDT.

Gavin Spencer will also be available for one-one-one meetings at the conference.

Promising preclinical data on new compounds for glaucoma presented at ARVO by Nicox

Novel nitric oxide donors NCX 667 and NCX 470 effective in lowering IOP
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that promising preclinical results from two novel nitric oxide-donors, NCX 667 and NCX 470, were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting,

Read more

Nicox’s Extraordinary and Ordinary Shareholder Meetings

Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0000074130, COX), has convened an ordinary and extraordinary shareholder meeting on Wednesday June 3, 2015 at 2:00 pm CET at the Hotel Mercure – rue Albert Caquot – 06560 Sophia Antipolis – France.
The documents mentioned in articles L.225-115, R. 225-81 and R. 225-83 of the French Code de commerce,

Read more

Nicox first quarter 2015 financial and business update

Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today reported its first quarter 2015 revenues and cash position and provided an update on its activities.
“We enjoyed an excellent start to 2015 across the different business activities of our Group” said Michele Garufi, Chairman and CEO of Nicox. “The successful financing completed in March demonstrated support for our strategy from international specialist investors,

Read more

Nicox 2014 Financial Results and Business Update

  • A year of strategic progress:
    • Positive phase 3 results for Vesneo™ (Bausch + Lomb); NDA submission on track for Q2 2015
    • Significant strengthening of ophthalmic therapeutics pipeline
    • Acquisition of Aciex Therapeutics, Doliage and Carragelose® eye drop (Xailin Viral)
    • In-licensing of AzaSite® and BromSite™ in Europe (Q1 2015)
  • 2014 revenues €6.0 million vs.
Read more

Nicox receives Orphan Drug Designation from FDA for naproxcinod in Duchenne Muscular Dystrophy

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: COX) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for naproxcinod for the treatment of Duchenne Muscular Dystrophy (DMD). ODD is a status granted to drugs or biological products that treat rare diseases or conditions. The designation qualifies the sponsor of the drug for various development incentives,

Read more

Nicox announces financing of €27 million to support its growth strategy

Not for distribution in or into the United States of America, Canada, Japan or Australia, except as permitted by applicable law
Participation of life science specialized investors, mainly from the US, strengthens shareholder base
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: COX), the international ophthalmic company, today announced a reserved capital increase of ordinary shares of the Company to specific categories of investors.

Read more

Nicox signs exclusive license agreement with InSite Vision for AzaSite® and BromSite™ in Europe

  • InSite grants Nicox exclusive license for AzaSite® (1% azithromycin), BromSite™ (0.075% bromfenac) and AzaSite Xtra™ (2% azithromycin) in Europe, Middle East and Africa
  • European regulatory filings for AzaSite® and BromSite™ planned by Q1 2016

Sophia Antipolis, France
Nicox S.A. (NYSE Euronext Paris: COX) today announced the signature of a license agreement with InSite Vision Inc.

Read more

Nicox holds successful pre-NDA meeting with FDA on AC-170 clinical package

Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has held a positive pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) regarding AC-170, a topical ocular formulation of cetirizine developed for the treatment of ocular itching associated with allergic conjunctivitis. The purpose of the meeting was to discuss the clinical package for AC 170,

Read more

Launch of new website www.nicox.es

Nicox is pleased to announce the launch of a new website dedicated to the group’s operations in Spain: www.nicox.es. This website is designed to provide corporate information as well as detailed information on our products to Spanish eye care practitioners. 

2014

Nicox expands Xailin™ range of ocular products

Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has further expanded its branded Xailin™ range of ocular products. This now comprises six products classed as medical devices: five ocular lubricants for dry eye symptoms and one eyewash. Xailin™ is a proprietary brand marketed by Nicox in the main European markets and through Nicox’s distributors in other international markets outside North America.

Read more

Acquisition of Nicox’s US ophthalmic diagnostics subsidiary by Valeant

  • Nicox to concentrate resources on its growing pipeline of ophthalmic therapeutics following recent acquisition of Aciex Therapeutics, Inc.
  • Transaction worth up to $20 million, including $10 million upfront plus potential sales-based milestone payments of up to $10 million

Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company,

Read more

Nicox announces third quarter 2014 financial results

  • Total revenues of €4.5 million in the 9 months to September 30 2014 (vs. €0.3 million in same period of 2013) 
  • Completion of Aciex Therapeutics, Inc. acquisition significantly strengthens Nicox’s therapeutic development pipeline 
  • Positive phase 3 results for VESNEO (latanoprostene bunod) support strong commercial potential
  • Acquisition of Doliage in France strengthens established revenue streams and marketing infrastructure 
Read more

Nicox completes the acquisition of Aciex Therapeutics, Inc.

Sophia Antipolis, France.
 
Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company. This acquisition represents a significant step forward in Nicox’s strategy of creating an international ophthalmic company and will significantly broaden and strengthen Nicox’s therapeutic development pipeline.
 
For more information,

Read more

Nicox’s shareholders approve acquisition of Aciex Therapeutics, Inc.

Sophia Antipolis, France.

 

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that its shareholders voted to approve the acquisition of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company, at the General Meeting held today October 22, 2014, with more than 97% of  votes in favour. The transaction is expected to be completed within the next few days,

Read more

Nicox’s Jerry St. Peter nominated to TFOS Corporate Advisory Board

Sophia Antipolis, France.

 

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that Jerry St. Peter, Executive Vice President and General Manager of Nicox’s US subsidiary Nicox Inc., has been nominated to the Corporate Advisory Board of the Tear Film & Ocular Surface Society (TFOS). TFOS is an international, non-profit eye health organization dedicated to advancing research and education related to the scientific field of the surface of the eye.

Read more

Nicox launches Xailin Gel, an innovative “preservative-free in the eye” dry eye lubricant

Sophia Antipolis, France.

 

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch in Europe of Xailin Gel, an innovative multidose carbomer gel lubricant (medical device) that becomes preservative-free in the eye. Once Xailin Gel is in contact with the eye surface, the substance released by the preservative is converted to water and oxygen by ocular enzymes,

Read more

Nicox continues expansion of international distribution network with exclusive agreement for Australia and New Zealand

This press release is being reissued with a corrected forward-looking statement
 
Sophia Antipolis, France.
 
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has entered into an exclusive agreement with OptiMed, a leading Australian company distributing ophthalmic diagnostic and therapeutic products, for the distribution of its product portfolio, including AdenoPlus® and the Xailin™ range,

Read more

Nicox provides information on approval of Aciex patents in the United States

Sophia Antipolis, France.

 

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has been informed by Aciex Therapeutics, Inc. that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent (No. 8,829,005) covering AC-170 Cetirizine Ophthalmic Compositions and a U.S. Patent (No. 8,765,725) covering AC-155 Fluticasone Propionate Nano-crystalline Compositions.

Read more

Nicox completes the acquisitions of Doliage and of the Carragelose® anti-viral eye drop program

Sophia Antipolis, France.
 
Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Doliage, a privately-held French ophthalmic company. The acquisition is part of Nicox’s strategy to develop an ophthalmic commercial infrastructure in the five major European markets and provides Nicox with an established and profitable ophthalmic business in France. 
 
For more information,

Read more

Nicox acquires Carragelose® anti-viral eye drop program

  • Acquires full rights from Marinomed Biotechnologie to Carragelose® anti-viral eye drop for potential application in the management of viral conjunctivitis 
  • Potential for European launch within 2 years as a medical device
  • Acquisition price of up to €5.3 million, including €2.65 million to be funded through newly issued Nicox shares

 

Read more

Nicox continues European ophthalmic expansion with acquisition of Doliage in France

  • Nicox to acquire 100% of French ophthalmic specialist Doliage for €5 million in newly issued Nicox shares 
  • Acquisition adds established, profitable ophthalmic product portfolio and complements Nicox’s existing commercial infrastructure in France with further upside potential in some export markets such as Southern Europe and North Africa
  • Doliage’s 2013 revenues totalled €2.6 million,
Read more

Nicox signs exclusive distribution agreement with Nitto Medic for AdenoPlus® in Japan

Sophia Antipolis, France.

 

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has entered into an exclusive agreement with Nitto Medic, a leading Japanese ophthalmic company, for the distribution in Japan of AdenoPlus®, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. Nicox has worldwide rights outside North America for AdenoPlus® as per an agreement with Rapid Pathogen Screening,

Read more

Nicox first half 2014 financial results

  • Revenues for the first six months totalled €2.6 million, reflecting the first full contribution of Eupharmed and of Nicox’s recently launched ophthalmic products
  • National US launches of diagnostic tests Sjö™ and RetnaGene™
  • Launch of European and ROW operations with AdenoPlus® and Xailin™
  • Top-line phase 3 results for latanoprostene bunod expected by year-end
  • Proposed acquisition of Aciex Therapeutics,
Read more

Nicox announces changes to its Board of Directors

Sophia Antipolis, France.

 

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announces the co option of Adrienne Graves and Luzi von Bidder to its Board of Directors. Mrs Graves and Mr von Bidder will replace Vaughn Kailian, who has been a member of the Board since 2001, and Vince Anido.

 

Vaughn Kailian has informed Nicox of his decision to step down from the Board of Directors with effect from August 11,

Read more

Nicox exercises option to co promote latanoprostene bunod with Bausch + Lomb in the US

Sophia Antipolis, France.
 
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced it has notified Bausch + Lomb (B+L), a division of Valeant Pharmaceuticals International, Inc., of its decision to exercise the option to co-promote latanoprostene bunod in the United States. Latanoprostene bunod is a nitric oxide (NO)-donating prostaglandin F2-alpha analog in phase 3 clinical development for the potential treatment of glaucoma and ocular hypertension which was licensed by Nicox to B+L in 2010.
 

Read more

Nicox gains expanded North American rights for Sjö™ from Immco Diagnostics

  • Nicox acquires extension of rights to market Sjö™ to all healthcare practitioners in North America for early detection of Sjögren’s syndrome
  • Wider availability and awareness expected to accelerate the identification and management of undiagnosed patients 

 

Sophia Antipolis, France.

 

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company,

Read more

Nicox focuses US operations on national launches of Sjö™ and RetnaGene™ and restructures RPS® licensing agreement

  • Nicox to focus US marketing resources on national roll-out of Sjö™ and launch of RetnaGene™
  • Rapid Pathogen Screening (RPS®) partnership for AdenoPlus® and two other products currently in development restructured in North America 

Sophia Antipolis, France.

 

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that Nicox’s subsidiary,

Read more

Launch of new website www.nicox.co.uk

Nicox is pleased to announce the launch of a new website dedicated to the group’s operations in the United Kingdom: www.nicox.co.uk. This website is designed to provide corporate information as well as detailed information on our products to UK eye care practitioners. If you are an eye care practitioner based in the UK and have any questions or comments,

Read more

Launch of new website www.mynicox.com

Nicox is pleased to announce the launch of a new website dedicated to the group’s operations in the United States: www.mynicox.com. This website is designed to provide corporate information as well as detailed information on our products to U.S. eye care practitioners. If you are an eye care practitioner based in the United States and have any questions or comments,

Read more

CORRECTED RELEASE – Nicox: Santen grants Eupharmed extension of exclusive rights to distribute Cationorm® in Italy

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) today issued a revised version of the press release dated May 28, 2014, to correct the number of newly issued Nicox shares to be paid to Fin Posillipo SPA in relation to the extension of the Cationorm® distribution agreement in Italy. The earn-out payment will be made in the form of 821,996 newly issued Nicox shares (not 823,483 as previously stated).

Read more

Nicox: Santen grants Eupharmed extension of exclusive rights to distribute Cationorm® in Italy

May 28, 2014.  

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announces that its wholly-owned Italian subsidiary Eupharmed has entered into an exclusive agreement with Santen SAS, enabling Eupharmed to continue to distribute Cationorm® in Italy.

Cationorm® is an innovative treatment for dry eye symptoms and is one of the highest-selling products in Eupharmed’s current portfolio.

Read more

Nicox appoints Evelyne Nguyen as CFO

  • Evelyne Nguyen brings 28 years of international experience, with a successful track record in financial management, execution of transactions and strategic planning
  • Stéphane Nicolas, Human Resources Senior Director of Nicox, also appointed to the Group’s Executive Committee

Read more

2013

Nicox completes the acquisition of Eupharmed

Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Eupharmed, a privately-held Italian ophthalmic company. This acquisition is part of Nicox’s strategy to establish sales infrastructure in the five major European markets and in the United States as it provides an established sales and marketing platform in Italy together with a broad portfolio of marketed eye care products.

Read more

Nicox establishes commercial operations in Italy through acquisition of Eupharmed

Nicox to acquire 100% of Eupharmed for €3.5 million in newly issued Nicox shares, plus potential additional earn-out payment. Acquisition of Eupharmed brings Nicox a direct marketing presence in Italy, an established product portfolio and sales platform for the launch of new products, including AdenoPlus® .
Sales from Eupharmed’s extensive ophthalmic portfolio including pharmaceuticals, medical devices and nutraceuticals totalled €3.6 million in 2012.
Italy’s ophthalmic market is one of the largest in Europe, with annual sales of more than €430 million1

Read more

Nicox First Half 2013 Financial Results and Business Update

Update of Nicox’s activities for the first six months of 2013

  • Expansion of the ophthalmic pipeline
  • Advanced clinical trials for latanoprostene bunod
  • Strengthened ophthalmology expertise
  • Nitric oxide-donating pipeline in other therapeutic areas

    As of June 30, 2013, the Group had cash and cash equivalents of €67.4 million, compared to €77.5 million on December 31, 2012.

    Read more

Nicox Strengthens Ophthalmic Portfolio with Immco Diagnostics’ Proprietary Test in the Dry Eye Market – Exclusive North American Agreement with rest of the world option

  • Exclusive rights to promote a proprietary laboratory test targeted at early diagnosis of Sjögren’s Syndrome, one of the most prevalent and underdiagnosed of all auto-immune diseases, with dry eye being among the early signs and symptoms
  • With more than 20 million patients suffering from dry eye in the US1, eye care practitioners are poised to play a significant and pivotal role in Sjögren’s Syndrome identification
  • 1 in 10 patients with dry eye symptoms may have undiagnosed Sjögren’s Syndrome2
  • Test was approved in the US in 2013 and available to doctors across North America. Commercial launch by Nicox expected in the second half of this year
  • Nicox to receive majority share of revenue

Read more

Nicox 2012 Financial Results and Business Update

Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) today announced its financial results for the year ended December 31, 2012, and provided an overview of its activities.

Michele Garufi, Chairman and CEO of Nicox, said: “In 2012, we made good progress in transforming Nicox into an international ophthalmic company driven by our world-leading proprietary research platform and our international network of collaborations with leading partners in the sector.

Read more

2012

Nicox launches AdenoPlus™ in the United States

Nicox S.A. (NYSE Euronext Paris: COX) today announces its United States (US) launch of AdenoPlus™,
the first and only FDA-cleared, CLIA-waived(1), rapid point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis. AdenoPlus™ is Nicox’s first product launch since it announced its strategy of becoming an international, late-stage development and commercial ophthalmic business, reflected by a new visual identity also unveiled today.

Read more

Nicox strengthens US commercial team

Nicox S.A. (NYSE Euronext Paris: COX) today announced the strengthening of its United States (US) business
operations with the appointment of three senior commercial executives at Nicox Inc., its US subsidiary. These follow the appointment of Jerry St. Peter as Executive Vice President and General Manager of Nicox Inc. in March 2012.
Nicox is building up its commercial organization in the US and in Europe following the recent in-licensing of
AdenoPlus™, a rapid point-of-care test for the detection of adenoviral conjunctivitis, which is already approved for marketing in the US and Europe. The launch in both markets is expected to take place later this year and will be supplemented in the future by other ophthalmic products, both diagnostic and therapeutic, that the Company plans to acquire or in-license.

Read more

Nicox first half 2012 financial results

Nicox S.A. (NYSE Euronext Paris: COX) today reports financial results for the six months ended June 30, 2012, and provided an update on its activities.
Key highlights for the first half of 2012
· Worldwide in-licensing agreement with RPS® for innovative diagnostic tests in the ocular field, including
AdenoPlus™
· Management team strengthened with the appointments of Jerry St.

Read more

Nicox signs worldwide licensing agreement with Rapid Pathogen Screening, Inc. for ophthalmic diagnostics

Nicox S.A. (NYSE Euronext Paris: COX) and Rapid Pathogen Screening, Inc (RPS®) today announce that they have entered into a licensing agreement giving NicOx access to RPS®’s innovative diagnostic tests. The agreement grants Nicox worldwide rights to unique point-of-care tests in the ocular field. The first of these tests is AdenoPlus™, which is already authorized for marketing in the United States (US) and in Europe. These tests are based on RPS®’s proprietary technology and enable rapid and accurate in-office diagnosis of specific ocular diseases and conditions.

Read more

Nicox reports first quarter 2012 financial results

Nicox made good progress during the first quarter of 2012, which was marked by the Company’s first step towards building an international ophthalmology company and by Bausch + Lomb’s decision to progress BOL-303259-X into phase 3, which supports the potential of our R&D platform in ophthalmology, said Michele Garufi, Chairman and CEO of Nicox.
If we decide to exercise the option to acquire Altacor,

Read more

Nicox provides update on U.S. regulatory status of naproxcinod

Nicox S.A. (NYSE Euronext Paris: COX) today announces that it met with the United States Food and Drug
Administration (FDA) on April 3, 2012, to discuss the proposed use of naproxcinod 375 mg twice daily (bid), for the treatment of signs and symptoms of osteoarthritis (OA) of the knee, under a proposed new NDA (New Drug Application) that would require additional clinical data prior to any such NDA submission.
The subject of the April 3, 2012 meeting was the required clinical data for the potential new NDA for naproxcinod 375 mg bid.

Read more

Nicox appoints Philippe Masquida EVP, Managing Director of European Operations; Next step in the Company’s strategy to create an international ophthalmology company

Nicox S.A. (NYSE Euronext Paris: COX) today announces the appointment of Philippe Masquida as Executive Vice President, Managing Director of European Operations. Mr. Masquida has over 22 years of senior international pharmaceutical experience and an impressive track record in ophthalmology.
Mr. Masquida will lead Nicox’s operations in Europe and in this role he will be managing the European subsidiaries. In addition he will be responsible, in coordination with the executive team of Nicox, for identifying and evaluating commercial opportunities in Europe as part of the Company’s strategy to build a late-stage ophthalmic portfolio. He will be part of Nicox’s Executive Committee and report to Michele Garufi, Chairman and CEO.

Read more

Jerry St. Peter appointed Executive Vice President and General Manager of Nicox Inc.

Nicox S.A. (NYSE Euronext Paris: COX) today announces the appointment of Jerry St. Peter as Executive Vice President and General Manager of Nicox Inc., the U.S. subsidiary of Nicox. Mr. St. Peter has a successful commercial track-record in specialty pharmaceutical companies, with an extensive knowledge of the ophthalmology market in the United States. In particular, he successfully developed the commercial unit of Inspire Pharmaceuticals, Inc., an ophthalmology-focused company acquired by Merck & Co. for $430 million in May 2011.
In tight collaboration with NicOx’s European headquarters, Mr. St. Peter will be responsible for identifying and evaluating North American opportunities than can be exploited globally, in order to build Nicox’s late-stage ophthalmic portfolio. Mr. St. Peter will also lead the development of Nicox’s U.S. ophthalmology business. He will be part of Nicox’s Executive Committee and will report to Michele Garufi, Chairman and CEO.

Read more

Nicox enters into option agreement to acquire Altacor as a first step towards building an international ophthalmology business

Nicox S.A. (NYSE Euronext Paris: COX) today announces that it has entered into an agreement to acquire 11.8% of the
shares of Altacor, a privately-held ophthalmology company based in the United Kingdom, and entered into an exclusive
option agreement to acquire the remaining shares of Altacor, marking the first step in its strategic plan to become a latestage
development and commercial ophthalmology company.
Altacor’s primary focus has been to build a specialty pharmaceutical company and has products, pipeline and
relationships in place to advance this significantly with Nicox. Altacor markets prescription and over-the-counter (OTC)
products for the treatment of dry eye in the United Kingdom and Ireland and has a diversified late-stage pipeline
including ALT-005, a surgical antiseptic, and SOLO, a device for the insertion of IntraOcular Lenses (IOLs). Under the
terms of the agreement, Nicox (the “Company”) is investing £2 million (approximately €2.4 million) in cash to acquire an
initial 11.8% stake in Altacor. In addition, Nicox has been granted an exclusive call option to acquire the remaining
shares of Altacor for an additional consideration of £9 million (approximately €10.8 million(1)) to be paid in Nicox shares,
cash or a combination of cash and shares at Nicox’s discretion. This option may be exercised by Nicox up until May 31,
2012. If agreed milestones are met, the consideration will be increased by up to £8.5 million.

Read more

Nicox, Bausch + Lomb Glaucoma Candidate BOL-303259-X Meets Primary Endpoint in Phase 2b Study; Bausch + Lomb to Pursue Global Phase 3 Development Program

Bausch + Lomb, the global eye health company, and Nicox S.A. (NYSE Euronext Paris: COX) today announced
positive top-line results from the phase 2b study conducted with BOL-303259-X, a novel nitric oxide-donating
prostaglandin F2-alpha analog, in patients with open-angle glaucoma or ocular hypertension. BOL-303259-X
(previously NCX 116) was licensed by Nicox to Bausch + Lomb in March 2010 (see Nicox and Bausch + Lomb press
release dated March 3, 2010). Bausch + Lomb will pay a $10 million milestone payment to Nicox and will initiate a
global phase 3 development program for BOL-303259-X.
The phase 2b study met its primary efficacy endpoint and showed positive results on a number of secondary
endpoints. The primary efficacy endpoint was the reduction in mean diurnal intraocular pressure (IOP) on day 28.
BOL-303259-X consistently lowered IOP in a dose-dependent manner. Two of the four doses tested showed greater
IOP reduction compared with Xalatan® 0.005%, with the differences reaching more than 1mmHg (statistical
significance: p<0.01).

Read more

Nicox 2011 Financial Results

2011 Financial Summary
Following the restructuring plan implemented by Nicox in late 2010, research and development costs and administrative and selling costs totalled €14.9 million in 2011, down sharply from €47.9 million in 2010.
In 2011, Nicox recorded a total net loss of €16.7 million, compared to a total net loss of €43.9 million in 2010. On December 31, 2011, the Company had cash and cash equivalents totalling €93.1 million, compared to €107.3 million on December 31, 2010.
No revenues were recorded in 2011, compared to €7.4 million in 2010, which related to the initial license payment received from Bausch + Lomb as part of the worldwide licensing agreement signed in March 2010.

Read more

2011

Update on Nicox’s business activities

Nicox S.A. (NYSE Euronext Paris: COX) today provides an update on its activities, including a continuing reorganization of its operations aimed at streamlining the organisation and ensuring the best use of existing cash resources.
In order to align Nicox’s structure with the corporate strategy, the Company is implementing a planned reduction of its workforce by approximately one third and is focusing its resources on its objective of creating a commercially-focused development organization.

Read more